
Scott Stromatt, M.D., CMO of GeneTx Biotherapeutics provided the following update:
“The first group of patients in the clinical trial of GTX-102 have received their first dose. The clinical trial is proceeding as planned and we are closely monitoring the COVID-19 pandemic and how it might impact this clinical study. Patient safety is paramount and we are making adjustments as necessary to continue the required monitoring while reducing the burden to families where possible. . . . The pandemic has slowed down the site activation process as each institution is addressing the COVID-19 pandemic in their region.”